Utilizing automated image analysis technology that identifies tumor and benign tissues, ProMark measures the quantitative expression levels of eight protein biomarkers that individually correlate with tumor aggressiveness and together predict your individual patient’s risk of aggressive disease.

Science:
After antigen retrieval, the tissue sections are subjected to multiplex immunofluorescent staining with monoclonal antibodies as well as DAPI using a proprietary assay format that enables the quantitative biomarker measurements in the “region of interest” on the tissue sections. The “raw” images of the stained sections are acquired on our image acquisition platform and then transferred to our advanced imaging platform, which through advanced object recognition and usage of our proprietary script enables digitalized quantitative measurements in the defined tissue sub-regions.